1. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Archives of General Psychiatry. 2003; 60: 39-47.
2. Carroll LJ, Cassidy JD, Cote P. Depression as a risk factor for onset of an episode of troublesome neck and low back pain. Pain. 2004; 107: 134-9.
3. Currie SR, Wang JL. More data on major depression as an antecedent risk factor for first onset of chronic back pain. Psychological Medicine. 2005; 35: 1275-82.
4. American Psychiatric Association. Diagnostic and 22. statistical manual of mental disorders, 4th edn. Arlington: American Psychiatric Association, 2000.
5. Currie SR, Wang JL. Chronic back pain and major 23. depression in the general Canadian population. Pain. 2004; 107: 54-60.
6. Dickens C, McGowan L, Dale S. Impact of depression on experimental pain perception: A systematic review of the 24. literature with meta-analysis. Psychosomatic Medicine. 2003; 65: 369-75.
7. Bar KJ, Brehm S, Boettger MK et al. Pain perception in major depression depends on pain modality. Pain. 2005; 25. 117: 97-103.
8. Bar KJ, Brehm S, Boettger MK et al. Decreased sensitivity to experimental pain in adjustment disorder. European 26. Journal of Pain. 2006; 10: 467-71.
9. Wasan AD, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain. 2005; 117: 450-61. 27.
10. Klossika I, Flor H, Kamping S et al. Emotional modulation of pain: a clinical perspective. Pain. 2006; 124: 264-8.
11. Meredith PJ, Strong J, FeeneyJA. The relationship of adult attachment to emotion, catastrophizing, control, threshold 28. and tolerance, in experimentally-induced pain. Pain. 2006; 120: 44-52.
12. Meredith P, Strong J, Feeney JA. Adult attachment, 29. anxiety, and pain self-efficacy as predictors of pain intensity and disability. Pain. 2006; 123: 146-54.
13. Zubieta JK, Smith YR, Bueller JA et al. Regional mu opioid receptor regulation of sensory and affective dimensions of 30. pain. Science. 2001; 293: 311-5.
* 14. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in 31.
health and disease. European Journal of Pain. 2005; 9: 463-84.
* 15. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron. 2007; 55: 377-91.
16. Zubieta JK, Heitzeg MM, Smith YR et al. COMT val158met 32. genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003; 299: 1240-3.
17. Fairhurst M, Wiech K, Dunckley P, Tracey I. Anticipatory 33. brainstem activity predicts neural processing of pain in humans. Pain. 2007; 128: 101-10.
18. Zubieta JK, Smith YR, Bueller JA etal. Mu-opioid receptor-mediated antinociceptive responses differ in men and women. Journal of Neuroscience. 2002; 22: 5100-7. 34.
19. Giesecke T, Gracely RH, Williams DA et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis and Rheumatism. 2005; 52: 1577-84.
20. Millan MJ. Descending control of pain. Progress in 35. Neurobiology. 2002; 66: 355-474.
21. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology. 1997; 340: 249-58.
Amir R, Argoff CE, Bennett GJ, Cummins TR. The role of sodium channels in chronic inflammatory and neuropathic pain. Journal of Pain. 2006; 7: S1-29. Li YF, Zhang YZ, Liu YQ et al. Inhibition of N-methyl-D-aspartate receptor function appears to be one of the common actions for antidepressants. Journal of Psychopharmacology. 2006; 20: 629-35. Zarrindast MR, Vousooghi N, Sahebgharani M. Imipramine-induced antinociception in the formalin test -Receptor mechanisms involved and effect of swim stress. Pharmacology. 2003; 68: 154-61. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry. 1996; 153: 311-20. Hubbard R, Farrington P, Smith C et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. American Journal of Epidemiology. 2003; 158: 77-84. Liu B, Anderson G, Mittmann N et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998; 351: 1303-7.
Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Archives of Internal Medicine. 1991; 151: 754-6.
Tata LJ, West J, Smith C et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005; 91: 465-71. Ray WA, Meredith S, Thapa PB et al. Cyclic antidepressants and the risk of sudden cardiac death. Clinical Pharmacology and Therapeutics. 2004; 75: 234-41. Chan GM, Stajic M, Marker EK et al. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: Analysis of medical examiner data. Academic Emergency Medicine. 2006; 13: 543-7. Krantz MJ, Lowery CM, Martell BA et al. Effects of methadone on QT-interval dispersion. Pharmacotherapy. 2005; 25: 1523-9.
Sindrup SH, Ejlertsen B, Froland A et al. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. European Journal of Clinical Pharmacology. 1989; 37: 151-3. Sindrup SH, Gram LF, Skjold T et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. British Journal of Clinical Pharmacology. 1990; 30: 683-91.
Sindrup SH, Tuxen C, Gram LF et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy European Journal of Clinical Pharmacology. 1992; 43: 251-5.
36. Max MB, Culnane M, Schafer SC et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987; 37: 589-96.
37. Max MB, Kishore-Kumar R, Schafer SC et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991; 45: 3-9.
38. Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. New England Journal of Medicine. 1992; 326: 1250-6.
39. Gomez-Perez FJ, Rull JA, Dies H et al. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain. 1985; 23: 395-400.
40. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. Journal of the American Medical Association. 1984; 251: 1727-30.
41. Vrethem M, Boivie J, Arnqvist H et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clinical Journal of Pain. 1997; 13: 313-23.
42. Sindrup SH, Bach FW, Madsen C et al. Venlafaxine versus imipramine in painful polyneuropathy - a randomized, controlled trial. Neurology. 2003; 60: 1284-9.
43. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clinical Journal of Pain. 2000; 16: 188-92.
44. Kishore-Kumar R, Max MB, Schafer SC et al. Desipramine relieves postherpetic neuralgia. Clinical Pharmacology and Therapeutics. 1990; 47: 305-12.
45. Max MB, Schafer SC, Culnane M et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988; 38: 1427-32.
46. Watson CP, Evans RJ, Reed K et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 1982; 32: 671-3.
47. Raja SN, Haythornthwaite JA, Pappagallo M et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002; 59: 1015-21.
48. Panerai AE, Monza G, Movilia P et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurologica Scandinavica. 1990; 82: 34-8.
49. Leijon G, Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine. Pain. 1989; 36: 27-36.
* 50. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999; 83: 389-400.
Antidepressants in the treatment of neuropathic pain. Basic and Clinical Pharmacology and Toxicology. 2005; 96: 399-409.
Finnerup NB, Otto M, McQuay HJ et al. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005; 118: 289-305.
Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. Journal of Psychiatry and Neuroscience. 2001; 26: 30-6.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews. 2005; CD005454.
Robinson LR, Czerniecki JM, Ehde DM et al. Trial of amitriptyline for relief of pain in amputees: Results of a ramdomized controlled study. Archives of Physical Medicine and Rehabilitation. 2004; 85: 1-6. Wilder-Smith CH, Hill LT, Laurent S. Postamputation pain and sensory changes in treatment-naive patients -characteristics and responses to treatment with tramadol, amitriptyline, and placebo. Anesthesiology. 2005; 103: 619-28.
Kieburtz K, Simpson D, Yiannoutsos C et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 1998; 51: 1682-8. Shlay JC, Chaloner K, Max MB et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy - a randomized controlled trial. Journal of the American Medical Association. 1998; 280: 1590-5. Cardenas DD, Warms CA, Turner JA et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain. 2002; 96: 365-73.
Rasmussen PV, Jensen TS, Sindrup SH, Bach FW. TDM-based imipramine treatment in neuropathic pain. Therapeutic Drug Monitoring. 2004; 26: 352-60. Atkinson JH, Slater MA, Williams RA et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998; 76: 287-96. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain. 2007; 130: 66-75. Atkinson JH, Slater MA, Wahlgren DR et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999; 83: 137-45. Hameroff SR, Weiss JL, Lerman JC et al. Doxepin's effects on chronic pain and depression: a controlled study. Journal of Clinical Psychiatry. 1984; 45: 47-53. Ward N, Bokan JA, Phillips M et al. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. Journal of Clinical Psychiatry. 1984; 45: 54-9.
Alcoff J, Jones E, Rust P, Newman R. Controlled trial of imipramine for chronic low back pain. Journal of Family Practice. 1982; 14: 841-6.
Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. Journal of International Medical Research. 1976; 4: 28-40.
Pheasant H, Bursk A, Goldfarb J et al. Amitriptyline and chronic low-back pain. A randomized double-blind crossover study. Spine. 1983; 8: 552-7.
Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain - a metaanalysis. Archives of Internal Medicine. 2002; 162: 19-24. Schnitzer TJ, Ferraro A, Hunsche E, Kong SX. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. Journal of Pain and Symptom Management. 2004; 28: 72-95. Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003; 28: 2540-5. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. Journal of the American Medical Association. 2004; 292: 2388-95. Carette S, Bell MJ, Reynolds WJ et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis and Rheumatism. 1994; 37: 32-40. Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis and Rheumatism. 1995; 38: 1211-7. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism. 1986; 29: 1371-7.
Goldenberg D, Mayskiy M, Mossey C et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism. 1996; 39: 1852-9. Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. Journal of Rheumatology Supplement. 1989; 19: 98-103. Jaeschke R, Adachi J, Guyatt G et al. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. Journal of Rheumatology. 1991; 18: 447-51.
Ginsberg F, Mancaux A, Joos E et al. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. Journal of Musculoskeletal Pain. 1996; 4: 37-47.
Hannonen P, Malminiemi K, Yli-Kerttula U et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. British Journal of Rheumatology 1998; 37: 1279-86. Kempenaers C, Simenon G, Vander Elst M et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology. 1994; 30: 66-72.
Arnold LM. Biology and therapy of fibromyalgia - new therapies in fibromyalgia. Arthritis Research and Therapy 2006; 8: 212.
O'Malley PG, Balden E, Tomkins G et al. Treatment of fibromyalgia with antidepressants - a meta-analysis. Journal of General Internal Medicine. 2000; 15: 659-66.
84. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001; 25: 871-80.
85. Puozzo C, Lens S, Reh C et al. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clinical Pharmacokinetics. 2005; 44: 977-88.
86. Goldstein DJ, Lu YL, Detke MJ etal. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005; 116: 109-18.
87. Raskin J, Pritchett YL, Wang FJ et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine. 2005; 6: 346-56.
88. Wernicke JF, Pritchett YL, D'Souza DN et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006; 67: 1411-20.
89. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study Pain. 2004; 110: 697-706.
90. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain. 2002; 6: 17-24.
91. Arnold LM, Lu YL, Crofford LJ et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism. 2004; 50: 2974-84.
92. Arnold LM, Rosen A, Pritchett YL et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005; 119: 5-15.
93. Gendreau RM, Thorn MD, Gendreau JF et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology. 2005; 32: 1975-85.
94. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Annals of Pharmacotherapy. 2003; 37: 1561-5.
95. Dwight MM, Arnold LM, O'Brien H et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 1998; 39: 14-7.
96. Detke MJ, Lu YL, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. Journal of Clinical Psychiatry. 2002; 63: 308-15.
97. Detke MJ, Lu YL, Goldstein DJ et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research. 2002; 36: 383-90.
98. Goldstein DJ, Mallinckrodt C, Lu YL, Demitrack MA. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. Journal of Clinical Psychiatry. 2002; 63: 225-31.
Goldstein DJ, Lu YL, Detke MJ et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004; 45: 17-28. 114.
Fava M, Mallinckrodt CH, Detke MJ et al. The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates? Journal of Clinical Psychiatry. 115.
Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R.
The association of depression and painful physical symptoms - a review of the European literature. European 116.
Psychiatry. 2006; 21: 379-88.
Brannan SK, Mallinckrodt CH, Brown EB et al. Duloxetine
60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. 117.
Journal of Psychiatric Research. 2005; 39: 43-53.
Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. American Journal of Psychiatry. 118.
Anjaneyulu M, Chopra K. Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin- 119.
induced diabetic mice. European Journal of Pharmacology. 2006; 538: 80-4.
Singh VP, Jain NK, Kulkarni SK. On the antinociceptive effect of fluoxetine, a selective serotonin reuptake 120.
inhibitor. Brain Research. 2001; 915: 218-26.
Lenkey N, Karoly R, Kiss JP et al. The mechanism of activity-dependent sodium channel inhibition by the 121.
antidepressants fluoxetine and desipramine. Molecular
Pharmacology. 2006; 70: 2052-63.
Garcia-Quetglas E, Azanza JR, Sadaba B et al.
Pharmacokinetics of tramadol enantiomers and their 122.
respective phase I metabolites in relation to CYP2D6
phenotype. Pharmacological Research. 2007; 55: 122-30.
Dannon PN, lancu I, Cohen A et al. Three year naturalistic 123.
outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry. 2004; 4: 16.
Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation 124.
antidepressants - meta-analysis. British Journal of
Psychiatry. 2006; 189: 393-8.
Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake 125.
inhibitors (SSR1s) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. 126.
British Medical Journal. 2005; 330: 385-388A.
Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. Journal of the American Medical
Association. 2004; 292: 338-43. 127.
Moller HJ. Evidence for beneficial effects of antidepressants on suicidality in depressive patients - A
systematic review. European Archives of Psychiatry and *128.
Clinical Neuroscience. 2006; 256: 329-43.
Moller HJ. Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A
systematic review. European Archives of Psychiatry and
Clinical Neuroscience. 2006; 256: 476-96.
Tiihonen J, Lonnqvist J, Wahlbeck K et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Archives of General
Psychiatry. 2006; 63: 1358-67.
Sindrup SH, Bjerre U, Dejgaard A et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clinical Pharmacology and Therapeutics. 1992; 52: 547-52.
Sindrup SH, Gram LF, Brosen K et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;
Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial. Journal of Pain. 2005; 6: 741-6.
Goldenberg D, Mayskiy M, Mossey C et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism. 1996; 39: 1852-9. Arnold LM, Hess EV, Hudson JI et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. American Journal of Medicine. 2002; 112: 191-7. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scandinavian Journal of Rheumatology. 1994; 23: 255-9. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia - a randomized, double blind, placebo-controlled study. European Journal of Pain. 2000; 4: 27-35.
Norregaard J, Volkmann H, Danneskioldsamsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995; 61: 445-9. Dickens C, Jayson M, Sutton C, Creed F. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics. 2000; 41 : 490-9.
Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. Journal of
Clinical Psychiatry. 2006; 67: 33-7.
Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001; 57: 1583-8.
Katz J, Pennella-Vaughan J, Hetzel RD et al. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. Journal of Pain. 2005; 6:
Fava M. Prospective studies of adverse events related to antidepressant discontinuation. Journal of Clinical Psychiatry. 2006; 67: 14-21.
Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. Journal of Psychiatry and Neuroscience. 2000; 25: 255-61.
129. Sternbach H. The serotonin syndrome. American Journal of Psychiatry. 1991; 148: 705-13.
130. Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. Journal of Clinical Psychiatry. 2006; 67: 8-13.
131. Rosenbaum JF, Fava M, Hoog SL et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological Psychiatry. 1998; 44: 77-87.
132. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of Affective Disorders. 2005; 89: 207-12.
*133. Schatzberg AF, Blier P, Delgado PL et al. Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research. Journal of Clinical Psychiatry. 2006; 67: 27-30.
134. Nieuwstraten C, Labiris NR, Holbrook A. Systematic overview of drug interactions with antidepressant medications. Canadian Journal of Psychiatry- Revue Canadienne De Psychiatrie. 2006; 51: 300-16.
135. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Annals of Pharmacotherapy. 2004; 38: 411-3.
136. Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. Annals of Pharmacotherapy. 2006; 40: 155-7.
137. Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs. Anesthesia and Analgesia. 2006; 103: 1466-8.
*138. Boyer EW, Shannon M. The serotonin syndrome. New England Journal of Medicine. 2005; 352: 1112-20.
*139. Dunkley EJC, Isbister GK, Sibbritt D et al. The Hunter
Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM - an International Journal of Medicine. 2003; 96: 635-42.
Was this article helpful?